Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Geary

Showing results (41-50 of 152) with videos related to

Pageof 16
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|November 16, 2023
Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modellingXiang Gao, John K Diep, Daniel A Norris, et al.
Oligonucleotides|December 2, 2010
In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenatesMin-Son Baek, Rosie Z Yu, Hans Gaus, et al.
Nucleic Acid Therapeutics|April 23, 2021
Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense OligonucleotidesCharvi Nanavati, Gina McMullen, Rosie Yu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 24, 2002
Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigsAraz A Raoof, Zeibun Ramtoola, Brain McKenna, et al.
Anti-Cancer Drug Design|July 1, 1997
Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotidesR S Geary, J M Leeds, S P Henry, et al.
Biochemical Pharmacology|April 28, 2009
Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTENRichard S Geary, Ed Wancewicz, John Matson, et al.
Microscopy Research and Technique|May 1, 1995
SEM comparison of Morpho butterfly dorsal and ventral scalesL Bingham, I Bingham, S Geary, et al.
Archives of Environmental Health|April 16, 1998
Maternal residential exposure to hazardous wastes and risk of central nervous system and musculoskeletal birth defectsE G Marshall, L J Gensburg, D A Deres, et al.
Biochemical Pharmacology|August 18, 2020
Antisense drug discovery and development technology considered in a pharmacological contextStanley T Crooke, Xue-Hai Liang, Rosanne M Crooke, et al.
Journal of Robotic Surgery|February 16, 2021
Uptake and outcomes of robotic gynaecological surgery in England (2006-2018): an account of Hospital Episodes Statistics (HES)D El-Hamamsy, R S Geary, I Gurol-Urganci, et al.
Pageof 16

Showing results (41-50 of 152) with videos related to

Sort By:
Pageof 16
Expert Opinion on Drug Metabolism & Toxicology|November 16, 2023
Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modellingXiang Gao, John K Diep, Daniel A Norris, et al.
Oligonucleotides|December 2, 2010
In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenatesMin-Son Baek, Rosie Z Yu, Hans Gaus, et al.
Nucleic Acid Therapeutics|April 23, 2021
Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense OligonucleotidesCharvi Nanavati, Gina McMullen, Rosie Yu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 24, 2002
Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigsAraz A Raoof, Zeibun Ramtoola, Brain McKenna, et al.
Anti-Cancer Drug Design|July 1, 1997
Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotidesR S Geary, J M Leeds, S P Henry, et al.
Biochemical Pharmacology|April 28, 2009
Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTENRichard S Geary, Ed Wancewicz, John Matson, et al.
Microscopy Research and Technique|May 1, 1995
SEM comparison of Morpho butterfly dorsal and ventral scalesL Bingham, I Bingham, S Geary, et al.
Archives of Environmental Health|April 16, 1998
Maternal residential exposure to hazardous wastes and risk of central nervous system and musculoskeletal birth defectsE G Marshall, L J Gensburg, D A Deres, et al.
Biochemical Pharmacology|August 18, 2020
Antisense drug discovery and development technology considered in a pharmacological contextStanley T Crooke, Xue-Hai Liang, Rosanne M Crooke, et al.
Journal of Robotic Surgery|February 16, 2021
Uptake and outcomes of robotic gynaecological surgery in England (2006-2018): an account of Hospital Episodes Statistics (HES)D El-Hamamsy, R S Geary, I Gurol-Urganci, et al.
Pageof 16